Lineage Cell Therapeutics, Inc. (LCTX)
| Market Cap | $201.12M-57.5% |
| Revenue (ttm) | $10.84M |
| Net Income | $1.75M |
| EPS | -$0.10 |
| Shares Out | 252.95M |
| PE Ratio | n/a |
| Forward PE | -7.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,762,959 |
| Open | $0.94 |
| Previous Close | $0.91 |
| Day's Range | $0.77 - $0.95 |
| 52-Week Range | $0.77 - $1.99 |
| Beta | 1.69 |
| Analysts | Strong Buy |
| Price Target | $5.50(+591.74%) |
| Earnings Date | Nov 12, 2026 |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Lineage Cell Therapeutics, Inc. Stock Analysis — InsiderScore
Lineage Cell Therapeutics, Inc. scored higher than 62% of companies evaluated by InsiderBuying, and ranked 29th out of 101 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Lineage Cell Therapeutics, Inc. bought $17.1K of stock across 1 purchase in the last 90 days, the largest of them $17.1K.
The average purchase added about 78% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LCTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LCTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LCTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LCTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LCTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LCTX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from LCTX’s recent data — informational, not investment advice
